Metabolomic Profiles on Antiblastic Cardiotoxicity: New Perspectives for Early Diagnosis and Cardioprotection

Fazzini, Luca;Caggiari, Ludovica;Deidda, Martino;Onnis, Carlotta;Saba, Luca;Mercuro, Giuseppe;Cadeddu Dessalvi, Christian
2022-01-01

Abstract

Antiblastic drugs-induced cardiomyopathy remains a relevant cause of morbidity and mortality, during and after chemotherapy, despite the progression in protective therapy against cardiovascular diseases and myocardial function. In the last few decades, many groups of researchers have focused their attention on studying the metabolic profile, first in animals, and, subsequently, in humans, looking for profiles which could be able to predict drug-induced cardiotoxicity and cardiovascular damage. In clinical practice, patients identified as being at risk of developing cardiotoxicity undergo a close follow-up and more tailored therapies. Injury to the heart can be a consequence of both new targeted therapies, such as tyrosine kinase inhibitors, and conventional chemotherapeutic agents, such as anthracyclines. This review aims to describe all of the studies carried on this topic of growing interest.
2022
Cadiotoxicity; Cardioprotection; Heart failure; Metabolomics
Files in This Item:
File Size Format  
jcm-11-06745.pdf

open access

Type: versione editoriale
Size 620.51 kB
Format Adobe PDF
620.51 kB Adobe PDF View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Questionnaire and social

Share on:
Impostazioni cookie